Charting New Courses: Immix Biopharma's Proposed Public Offering of Common Stock.
In a significant announcement made recently, Immix Biopharma Inc., a clinical-stage biopharmaceutical company pioneering in cell therapies for autoimmune disease, has declared its intention of floating an underwritten p...
Feb 5, 2024
• Major Pharmaceutical Preparations Industry
Announcement
Immix Biopharma